[8-K] Genprex, Inc. Reports Material Event

Rhea-AI Filing Summary

Genprex, Inc. (GNPX) effected a one-for-fifty reverse stock split of its common stock, effective at 12:01 a.m. on October 21, 2025. The action consolidates every 50 pre-split shares into 1 share.

After giving effect to the reverse split, the company reports 1,004,326 shares outstanding as of October 21, 2025, prior to any rounding of fractional shares. The filing lists no other corporate changes or transactions related to this event.

Insights

Equity Capital Markets Analyst

Reverse split 1:50 completed; 1,004,326 shares post-split.

Genprex completed a 1-for-50 reverse stock split effective at 12:01 a.m. on October 21, 2025. This reduces the number of outstanding common shares and increases the per-share price mechanically without changing the company’s market value.

The company reports 1,004,326 shares outstanding as of October 21, 2025, before any rounding for fractional shares. No proceeds or other transactions are described in connection with this action.

Subsequent disclosures may clarify post-rounding share count, but the core mechanics are set by the completed split.

false 0001595248 0001595248 2025-10-21 2025-10-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

October 21, 2025

Date of report (Date of earliest event reported)

GENPREX, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-38244	90-0772347
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification Number)
3300 Bee Cave Road, #650-227, Austin, TX		78746
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (512) 537-7997

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		GNPX		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As of 12:01 a.m. on October 21, 2025, Genprex, Inc., a Delaware corporation (the “Company”), effected the previously disclosed one-for-fifty (1:50) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”).  After giving effect to the Reverse Stock Split, as of October 21, 2025, and prior to any rounding applied to any fractional shares resulting from the Reverse Stock Split, the Company has 1,004,326 shares of Common Stock outstanding.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GENPREX, INC.
Date: October 21, 2025	By:	/s/ Ryan Confer
		Ryan Confer
		Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

FAQ

What did Genprex (GNPX) announce?

Genprex effected a one-for-fifty (1:50) reverse stock split of its common stock, effective at 12:01 a.m. on October 21, 2025.

What is Genprex’s share count after the reverse split?

After the split, Genprex reports 1,004,326 shares outstanding as of October 21, 2025, prior to any rounding of fractional shares.

Does the reverse split generate proceeds for Genprex?

No. The disclosure lists a completed reverse split and does not describe any cash proceeds.

How does a 1-for-50 reverse split work for GNPX?

Every 50 pre-split shares are combined into 1 post-split share; the per-share price adjusts mechanically while total market value remains unchanged by the split itself.

Were there other corporate actions disclosed with the split?

No additional transactions or changes were described alongside the reverse split in this disclosure.